As of March 31, 2026, Avanos Medical, Inc. carries a market capitalization of 653.89M, placing it among publicly traded companies globally. Its enterprise value stands at 726.69M, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.
| Market Cap | 653.89M |
| Enterprise Value | 726.69M |
Avanos Medical, Inc.'s next confirmed earnings release is scheduled for August 11, 2026.
| Earnings Date | 8/11/2026 |
As of March 31, 2026, Avanos Medical, Inc. has 46.67M shares outstanding.
| Shares Outstanding | 46.67M |
These figures are as of March 31, 2026. The price-to-sales ratio is 0.91, and the price-to-book ratio stands at 0.84.
| PS Ratio | 0.91 |
| PB Ratio | 0.84 |
| P/TBV Ratio | 2.39 |
| P/FCF Ratio | 17.81 |
| P/OCF Ratio | 17.71 |
These figures are as of March 31, 2026. The EV/Sales ratio of 1.02 reflects the premium investors pay for the company's revenue stream, a useful check when earnings are depressed or negative. These enterprise value multiples are built on an enterprise value of 726.69M versus a market cap of 653.89M, with the gap driven by net debt and cash on the balance sheet.
| EV / Sales | 1.02 |
As of March 31, 2026, Avanos Medical, Inc. maintains a current ratio of 2.48, meaning it holds 2.5x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 17.70, indicating elevated leverage, while an interest coverage ratio of -3.26 demonstrates limited ability to service its debt obligations.
| Current Ratio | 2.48 |
| Quick Ratio | 1.29 |
| Debt / Equity | 17.70 |
| Debt / EBITDA | -5.89 |
| Interest Coverage | -3.26 |
Over the twelve months ended March 31, 2026, Avanos Medical, Inc. posted a negative return on equity (ROE) of -9.18, meaning shareholder capital produced losses rather than profits. Return on assets (ROA) is negative at -6.90, reflecting losses generated across the asset base. The company generates approximately 317,190.96 in revenue per employee across its workforce of 2,257.00, a quick read on workforce productivity versus industry peers. Inventory turnover of 2.56 indicates how many times Avanos Medical, Inc. sells and replaces its inventory over a year, a key working capital efficiency ratio.
| Return on Equity (ROE) | -9.18 |
| Return on Assets (ROA) | -6.90 |
| Revenue Per Employee | 317,190.96 |
| Employee Count | 2,257.00 |
| Inventory Turnover | 2.56 |
Over the twelve months ended March 31, 2026, Avanos Medical, Inc. recorded 6.10M in income tax expense. The company reported a pretax loss of -68.30M and -74.40M in bottom-line net income, so the effective tax rate carries little signal until profitability returns.
| Income Tax | 6.10M |
As of the close on July 24, 2026, Avanos Medical, Inc.'s stock has gained approximately 110.35% over the past 52 weeks. The 50-day moving average sits at 24.90, while the 200-day moving average is 16.92.
| 52-Week Price Change | 110.35% |
| 50-Day Moving Average | 24.90 |
| 200-Day Moving Average | 16.92 |
Over the twelve months ended March 31, 2026, Avanos Medical, Inc. generated 715.90M in revenue and converted that into -74.40M in net income, yielding earnings per share of -1.59. EBITDA reached -23.50M, while operating income came in at 14.00M.
| Revenue | 715.90M |
| Gross Profit | 358.30M |
| Operating Income | 14.00M |
| Pretax Income | -68.30M |
| Net Income | -74.40M |
| EBITDA | -23.50M |
| EBIT | -63.00M |
| Earnings Per Share (EPS) | -1.59 |
As of March 31, 2026, Avanos Medical, Inc. holds 65.60M in cash and equivalents against 138.40M in total debt, resulting in a net debt position of 32.60M. Total book value stands at 782.10M, with working capital of 193.80M providing operational flexibility.
| Cash & Cash Equivalents | 65.60M |
| Total Debt | 138.40M |
| Net Debt | 32.60M |
| Equity (Book Value) | 782.10M |
| Book Value Per Share | 16.76 |
| Working Capital | 193.80M |
Avanos Medical, Inc. produced 36.70M in operating cash flow over the twelve months ended March 31, 2026.
| Operating Cash Flow | 36.70M |
| Free Cash Flow | 36.70M |
| FCF Per Share | 0.79 |
Over the twelve months ended March 31, 2026, Avanos Medical, Inc. posted a gross margin of 50.05, reflecting its pricing power and cost economics. The operating margin of 1.96 and net profit margin of -10.39 provide insight into operational efficiency.
| Gross Margin | 50.05 |
| Operating Margin | 1.96 |
| Pretax Margin | -9.54 |
| Profit Margin | -10.39 |
| EBITDA Margin | -3.28 |
These figures cover the twelve months ended March 31, 2026. Free cash flow yield stands at 5.62, showing how much cash the business generates relative to its market value - dividends covered by free cash flow are generally more durable than those funded by debt. Total shareholder yield reaches 1.70, combining dividends paid with share buybacks and debt reduction for a fuller picture of capital returned to Avanos Medical, Inc. shareholders.
| Shareholder Yield | 1.70 |
| FCF Yield | 5.62 |
As of March 31, 2026, Avanos Medical, Inc. has an Altman Z-Score of 1.30, below the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.
| Altman Z-Score | 1.30 |